胰腺腺鳞癌临床特征的病例对照研究

目的:分析胰腺腺鳞癌与胰腺导管腺癌的临床病理学特征,探究两者预后的差异性。方法:回顾性分析2014年8月至2019年4月于天津医科大学肿瘤医院行根治性手术的26例胰腺腺鳞癌及26例胰腺导管腺癌患者的临床病理特征,并按1:1比例行配对研究,每个对子的特征包括术前ECOG评分、年龄、性别、肿瘤位置、肿瘤大小、TNM分期、CA19-9、CEA,对比分析两组的预后差异。结果:两组均有女性7例,男性19例;肿瘤位于胰头者12例,胰体尾者14例;TNM分期:Ⅰb期13例,Ⅱa期6例,Ⅱb期6例,Ⅲ期1例。胰腺导管腺癌组肿瘤大小平均值为3.9 cm,胰腺腺鳞癌肿瘤大小平均值为4.4 cm。两组患者均行根治性手术,其中胰腺腺鳞癌组7例行联合脏器切除术。生存分析结果示胰腺腺鳞癌中位生存期为8.5个月,胰腺导管腺癌中位生存期为19个月(HR:0.442,95%CI:0.224~0.872;P=0.019)。结论:胰腺腺鳞癌多见于男性,与胰腺导管腺癌相比,预后较差,但无特异性临床表现。

Clinical characteristics of adenosquamous carcinoma of the pancreas: a case-control study

  Objective  To analyze the clinical characteristics of adenosquamous carcinoma of the pancreas (ACP) and pancreatic ductal adenocarcinoma (PDA), and to explore the differences in prognosis between the two types.  Methods  The clinical and pathological characteristics of 26 cases with ACP (Group A) and another 26 with PDA (Group B), both of whom underwent radical surgery at Tianjin Medical University Cancer Hospital from August 2014 to April 2019, were retrospectively analyzed, and were matched according to the ratio of one to one. In our study, the characteristics of each pair included preoperative ECOG score, age, gender, the location and size of the tumors, TNM staging, CA19-9, CEA. The prognostic differences between the two groups were compared and analyzed.  Results  There were 7 females and 19 males in both groups, among which 12 had lesions in the head of the pancreas and 14 in the tail of the pancreas; TNM staging: 13 in stageⅠb, 6 in stage Ⅱa, 6 in stage Ⅱb, and 1 in stage Ⅲ. The average tumor size was 3.9 cm in the Group B, and 4.4 cm in the Group A. Radical surgery was performed in the patients of both groups, and among them 7 patients in Group A received combined organ resections. Survival analysis showed that the median survival time was 8.5 months in Group A and 19 moths in Group B (HR: 0.442; 95% CI: 0.224-0.872; P=0.019).  Conclusions  ACP is more common in the males and its The prognosis is worse compared with PDA, but it has no specific clinical manifestations.